Cargando…

ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein

BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ patholog...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonvicini, Gillian, Syvänen, Stina, Andersson, Ken G., Haaparanta-Solin, Merja, López-Picón, Francisco, Sehlin, Dag
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791759/
https://www.ncbi.nlm.nih.gov/pubmed/36567338
http://dx.doi.org/10.1186/s40035-022-00324-y
_version_ 1784859478790766592
author Bonvicini, Gillian
Syvänen, Stina
Andersson, Ken G.
Haaparanta-Solin, Merja
López-Picón, Francisco
Sehlin, Dag
author_facet Bonvicini, Gillian
Syvänen, Stina
Andersson, Ken G.
Haaparanta-Solin, Merja
López-Picón, Francisco
Sehlin, Dag
author_sort Bonvicini, Gillian
collection PubMed
description BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ pathology in mouse models of Alzheimer’s disease (AD). This study aimed to determine if this strategy would be as sensitive in rats and to assess how TfR affinity affects BBB transport of bispecific immunoPET radioligands. METHODS: Two affinity variants of the rat TfR antibody, OX26, were chemically conjugated to a F(ab′)(2) fragment of the anti-Aβ antibody, bapineuzumab (Bapi), to generate two bispecific fusion proteins: OX26(5)-F(ab′)(2)-Bapi and OX26(76)-F(ab′)(2)-Bapi. Pharmacokinetic analyses were performed 4 h and 70 h post-injection of radioiodinated fusion proteins in wild-type (WT) rats. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi was administered to TgF344-AD and WT rats for in vivo PET imaging. Ex vivo distribution of injected [(124)I]I-OX26(5)-F(ab′)(2)-Bapi and Aβ pathology were assessed. RESULTS: More [(125)I]I-OX26(5)-F(ab′)(2)-Bapi was taken up into the brain 4 h post-administration than [(124)I]I-OX26(76)-F(ab′)(2)-Bapi. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi PET visualized Aβ pathology with significantly higher signals in the TgF344-AD rats than in the WT littermates without Aβ pathology. The PET signals significantly correlated with Aβ levels in AD animals. CONCLUSION: Affinity to TfR affects how efficiently a TfR-targeting bispecific fusion protein will cross the BBB, such that the higher-affinity bispecific fusion protein crossed the BBB more efficiently. Furthermore, bispecific immunoPET imaging of brain Aβ pathology using TfR-mediated transport provides good imaging contrast between TgF344-AD and WT rats, suggesting that this immunoPET strategy has the potential to be translated to higher species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00324-y.
format Online
Article
Text
id pubmed-9791759
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97917592022-12-27 ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein Bonvicini, Gillian Syvänen, Stina Andersson, Ken G. Haaparanta-Solin, Merja López-Picón, Francisco Sehlin, Dag Transl Neurodegener Research BACKGROUND: Hijacking the transferrin receptor (TfR) is an effective strategy to transport amyloid-beta (Aβ) immuno-positron emission tomography (immunoPET) ligands across the blood–brain barrier (BBB). Such ligands are more sensitive and specific than small-molecule ligands at detecting Aβ pathology in mouse models of Alzheimer’s disease (AD). This study aimed to determine if this strategy would be as sensitive in rats and to assess how TfR affinity affects BBB transport of bispecific immunoPET radioligands. METHODS: Two affinity variants of the rat TfR antibody, OX26, were chemically conjugated to a F(ab′)(2) fragment of the anti-Aβ antibody, bapineuzumab (Bapi), to generate two bispecific fusion proteins: OX26(5)-F(ab′)(2)-Bapi and OX26(76)-F(ab′)(2)-Bapi. Pharmacokinetic analyses were performed 4 h and 70 h post-injection of radioiodinated fusion proteins in wild-type (WT) rats. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi was administered to TgF344-AD and WT rats for in vivo PET imaging. Ex vivo distribution of injected [(124)I]I-OX26(5)-F(ab′)(2)-Bapi and Aβ pathology were assessed. RESULTS: More [(125)I]I-OX26(5)-F(ab′)(2)-Bapi was taken up into the brain 4 h post-administration than [(124)I]I-OX26(76)-F(ab′)(2)-Bapi. [(124)I]I-OX26(5)-F(ab′)(2)-Bapi PET visualized Aβ pathology with significantly higher signals in the TgF344-AD rats than in the WT littermates without Aβ pathology. The PET signals significantly correlated with Aβ levels in AD animals. CONCLUSION: Affinity to TfR affects how efficiently a TfR-targeting bispecific fusion protein will cross the BBB, such that the higher-affinity bispecific fusion protein crossed the BBB more efficiently. Furthermore, bispecific immunoPET imaging of brain Aβ pathology using TfR-mediated transport provides good imaging contrast between TgF344-AD and WT rats, suggesting that this immunoPET strategy has the potential to be translated to higher species. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-022-00324-y. BioMed Central 2022-12-26 /pmc/articles/PMC9791759/ /pubmed/36567338 http://dx.doi.org/10.1186/s40035-022-00324-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bonvicini, Gillian
Syvänen, Stina
Andersson, Ken G.
Haaparanta-Solin, Merja
López-Picón, Francisco
Sehlin, Dag
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title_full ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title_fullStr ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title_full_unstemmed ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title_short ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein
title_sort immunopet imaging of amyloid-beta in a rat model of alzheimer’s disease with a bispecific, brain-penetrating fusion protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791759/
https://www.ncbi.nlm.nih.gov/pubmed/36567338
http://dx.doi.org/10.1186/s40035-022-00324-y
work_keys_str_mv AT bonvicinigillian immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein
AT syvanenstina immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein
AT anderssonkeng immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein
AT haaparantasolinmerja immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein
AT lopezpiconfrancisco immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein
AT sehlindag immunopetimagingofamyloidbetainaratmodelofalzheimersdiseasewithabispecificbrainpenetratingfusionprotein